Daiichi, AstraZeneca Drop on Concern Over Lung-Cancer Drug
Daiichi Sankyo Co. and partner AstraZeneca Plc shares fell the most in years after a study of their highly-anticipated lung cancer medicine raised questions about its safety and effectiveness.










